A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Research type
Research Study
Full title
A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers
IRAS ID
1008066
Contact name
Shay Shemesh
Contact email
Sponsor organisation
Nuvectis Pharma, Inc.
Research summary
This clinical study is looking at (researching) a new investigational drug called NXP900. This is a new anti-cancer treatment that showed promise in laboratory studies. We now wish to find out if it will be safe and useful in treating patients with cancer. This is the first time NXP900 will be given to human patients.
The three main aims of this clinical study are to find out:
• The maximum dose that can be given safely to patients.
• More about the potential side effects of NXP900 and how they can be managed.
• What happens to NXP900 inside the body.
This information will help us decide how much and how often to give NXP900 to patients in future clinical studies.
In total we plan to recruit about 40 patients into this clinical study. Multiple hospitals in the United Kingdom and the United States may take part in this study. Additional countries may take part if we feel this is necessary.
This clinical study is called a ‘dose escalation study’ where increasing doses of NXP900 will be given to patients taking part to find a dose that can be taken with limited side effects while showing signs of NXP900 activity against cancer cells.REC name
South Central - Oxford B Research Ethics Committee
REC reference
23/SC/0193
Date of REC Opinion
17 Oct 2023
REC opinion
Further Information Favourable Opinion